TET2 Antikörper (Internal Region)

Produktnummer ABIN569654

Der Ziege Polyklonal anti-TET2 Antikörper wird verwendet zum Nachweis von TET2 in Proben von Human, Maus und Hund. Er wurde validiert für IHC (p) und EIA.

Kurzübersicht für TET2 Antikörper (Internal Region) (ABIN569654)

Target: TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))

Reaktivität: Human, Maus, Hund

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser TET2 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Produktdetails anti-TET2 Antikörper

Bindungsspezifität: Internal Region

Sequenz: C-PHPQSNNDQQ REGSF

Spezifität: This antibody is expected to recognize both reported isoforms (NP_001120680.1 and NP_060098.3).

Kreuzreaktivität (Details): Species reactivity (expected):Mouse and Canine (Dog).
Species reactivity (tested):Human.

Aufreinigung: Ammonium Sulphate Precipitation followed by antigen Affinity Chromatography using the immunizing peptide

Immunogen: Peptide with sequence from the internal region of the protein sequence according to NP_001120680.1 and NP_060098.3. Genename: TET2

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Tris saline, pH ~7.3 with 0.02 % Sodium Azide and 0.5 % BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu TET2

Target: TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))

Andere Bezeichnung: TET2

Hintergrund: TET2 is frequently mutated in myelodysplastic syndromes, a heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. It Catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is Broadly expressed. Highly expressed in hematopoietic cells, highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes.Synonyms: KIAA1546, Methylcytosine dioxygenase TET2

Gen-ID: 54790

NCBI Accession: NP_001120680

UniProt: Q6N021

Pathways: Warburg Effekt